title: Blood Donors on Medication - an Approach to Minimize Drug Burden for Recipients of Blood Products and to Limit Deferral of Donors.
abstract: BACKGROUND: Blood products derived from donors on medication can contain drugs which might pose a risk for the recipients or influence the quality of the product itself. MATERIAL AND METHODS: To judge the eligibility of blood donors on medication, 4 drug classes have been formed with respect to their pharmacological properties, and blood products have been divided in accordance with their single-donor plasma contents. RESULTS: For drugs with dose-dependent pharmacodynamics, no deferral periods are necessary for donation of blood products containing less than 50 ml single-donor plasma for application to adults. Waiting periods of t(max) + 5 t(1/2) were calculated for the other blood products. Teratogenic drugs do not require special considerations (exception: retinoids, thalidomide and lenalidomide, dutasteride or finasteride with waiting periods for all blood products). A deferral period of t(max) + 24 t(1/2) is proposed for every blood product from blood donors on genotoxic drugs. Drugs without systemic effects can be neglected. Irreversible inhibitors of platelet function cause a 10-day waiting period if production of platelet concentrates is intended. CONCLUSION: Donors on medication are allowed to donate blood for blood products containing less than 50 ml plasma of a single donor, like red blood cell concentrates, for the use in adults without deferral periods, except those taking retinoids, thalidomide, lenalidomide, dutasteride, finasteride, or genotoxic drugs.
authors.affiliation: Institut für Pharmakologie und Toxikologie der Bundeswehr, München, Germany.
authors.forename: Christian D K
authors.initials: CD
authors.lastname: Becker
authors.forename: Dirk O
authors.initials: DO
authors.lastname: Stichtenoth
authors.forename: Michael G
authors.initials: MG
authors.lastname: Wichmann
authors.forename: Christof
authors.initials: C
authors.lastname: Schaefer
authors.forename: Ladislaus
authors.initials: L
authors.lastname: Szinicz
references.citation: Vox Sang. 1982;43(3):138-41
references.pmid: 7147856
references.citation: Drugs. 1999 Jan;57(1):111-26
references.pmid: 9951956
references.citation: J Clin Pharmacol. 1998 Oct;38(10):926-30
references.pmid: 9807973
references.citation: Clin Chem. 1987 Jan;33(1):189
references.pmid: 3802478
references.citation: Eur J Clin Pharmacol. 2001 Sep;57(6-7):433-40
references.pmid: 11699606
references.citation: Am J Med. 2006 Feb;119(2):113-6
references.pmid: 16443409
references.citation: Acta Paediatr. 2006 May;95(5):600-13
references.pmid: 16825142
references.citation: Chest. 2001 Jan;119(1 Suppl):39S-63S
references.pmid: 11157642
references.citation: Lancet. 1989 Jul 8;2(8654):93-4
references.pmid: 2567883
references.citation: J Clin Pathol. 1982 Jan;35(1):59-62
references.pmid: 7061719
references.citation: Ann Allergy. 1971 Nov;29(11):598-601
references.pmid: 5121565
references.citation: Teratology. 1997 Feb;55(2):119-31
references.pmid: 9143092
references.citation: Transfusion. 2006 Aug;46(8):1402-7
references.pmid: 16934078
references.citation: Scand J Prim Health Care. 2003 Sep;21(3):153-8
references.pmid: 14531506
references.citation: Blood. 1969 May;33(5):649-61
references.pmid: 5779153
references.citation: Thromb Haemost. 2006 Jun;95(6):949-57
references.pmid: 16732373
references.citation: Vox Sang. 1980;38(5):284-7
references.pmid: 7415074
references.citation: Am J Med. 2006 Sep;119(9):719-27
references.pmid: 16945603
references.citation: Z Kinderheilkd. 1954;74(6):610-21
references.pmid: 13227161
references.citation: Transfusion. 1977 Nov-Dec;17(6):598-601
references.pmid: 595114
references.citation: Intensive Care Med. 2001 May;27(5):925-9
references.pmid: 11430552
references.citation: CMAJ. 1986 Aug 1;135(3):215-6
references.pmid: 3730981